This article is more than 5 years old. Information may no longer be current.
Cell differentiation, IL-1β expression influence outcomes after MACT
Click Here to Manage Email Alerts
Cell differentiation and interleukin-1β expression influenced clinical outcomes up to 5 years after matrix-associated chondrocyte transplantation, according to a recently published study.
Researchers performed preoperative clinical assessments on 27 patients who underwent matrix-associated chondrocyte transplantation (MACT) of the tibiofemoral joint area of the knee, as well as 6 months, 12 months, 24 months and 60 months after transplantation. The researchers used the Knee Injury and Osteoarthritis Outcome Score, IKDC Subjective Knee Form, Noyes sports activity rating scale, Brittberg clinical score and a WAS for pain. At 1 year and 5 years, researchers assessed the quality of repair tissue by MRI using magnetic resonance observation of cartilage repair tissue (MOCART) scores. Real-time polymerase chain reaction in transplant residuals determined cell differentiation, aggrecan and interleukin (IL)-1β and were correlated with outcomes.
Researchers found the largest improvements in clinical scores were within the first year, while a stable improvement was reached 2 years postoperatively until 5 years after transplantation. There was a significant positive correlation between cell differentiation and nearly all clinical scores at different time points, but especially after 12 months. IL-1β expression negatively influenced clinical outcomes at 24 months and 60 months postoperatively. They found no correlation between MOCART score and outcomes or gene expression.
“Our data demonstrate that cell differentiation and IL-1β expression influence clinical outcomes up to 5 years after MACT. Efforts to increase cell differentiation before transplantation should therefore be forced to further improve clinical results,” the researchers wrote. “The use of osteoarthritic chondrocytes, however, seems not to be suitable for MACT as long as techniques capable of reducing proinflammatory cytokine expression such as IL-1β have not been developed.”
Disclosure: The study was supported by the Department of Trauma Surgery at the Medical University of Vienna.
Click Here to Manage Email Alerts